Non-peptide arginine-vasopressin antagonists: the vaptans (Q34777664)

4 August 2017

1 reference

title

Non-peptide arginine-vasopressin antagonists: the vaptans (English)

1 reference

4 August 2017

0 references

3

Gilbert Vassart

1 reference

4 August 2017

Guy Decaux

1

1 reference

PubMed ID

18468546

4 August 2017

Alain Soupart

series ordinal

2

1 reference

PubMed ID

18468546

4 August 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

4 August 2017

1 reference

4 August 2017

371

1 reference

4 August 2017

9624

1 reference

4 August 2017

1624-1632

1 reference

Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

The central vasopressinergic system: examining the opportunities for psychiatric drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Pancreatic vasopressin V1breceptors: characterization in In-R1-G9 cells and localization in human pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Vasopressin antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Vasopressin V2 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Vaptans and the treatment of water-retaining disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Vasopressin receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Evaluation and management of hyponatremia: an emerging role for vasopressin receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Vasopressin antagonists: role in the management of hyponatremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Molecular biology of hereditary diabetes insipidus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Nephrogenic syndrome of inappropriate antidiuresis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

OPC-21268, an Orally Effective, Nonpeptide Vasopressin V1 Receptor Antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

In vivo and in vitro effects of AVP and V1a receptor antagonist on Cushing's syndrome due to ACTH-independent bilateral macronodular adrenocortical hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Pharmacologic management of Cushing syndrome : new targets for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

New approach to disturbances in the plasma sodium concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Conivaptan: a selective vasopressin antagonist for the treatment of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Neurohormonal inhibition in heart failure: insights from recent clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanil ide derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Vasopressin antagonists in polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

1 reference

7 January 2021

Hyponatremia in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Neurological impact of vasopressin dysregulation and hyponatremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Admission hyponatremia in the elderly: factors influencing prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Treatment of symptomatic hyponatremia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Management of severe hyponatremia: rapid or slow correction?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

The effects of several vasopressin receptor antagonists on normal intraocular pressure and the intraocular distribution of vasopressin receptor subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

The effects of V2 antagonist (OPC-31260) on endolymphatic hydrops

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Participation of vasopressin in the development of cerebral vasospasm in a rat model of subarachnoid haemorrhage.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

Oxytocin- and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960695-9

7 January 2021

10.1016/S0140-6736(08)60695-9

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

18468546